Merck's KEYTRUDA® (pembrolizumab) Receives 30th Approval From European Commission With Two New Indications in Gynecologic CancersBusiness Wire • 10/24/24
CDC'S ACIP Recommends Merck's CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for Pneumococcal Vaccination in Adults 50 Years of Age and OlderBusiness Wire • 10/23/24
Gilead, MRK Report Data From Investigational Combination Study for HIVZacks Investment Research • 10/21/24
Gilead and Merck Announce Phase 2 Data Showing a Treatment Switch to an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression in Adults at Week 48Business Wire • 10/19/24
Merck says experimental RSV treatment protected infants in trial, paving way for potential approvalCNBC • 10/17/24
Merck's Clesrovimab (MK-1654), an Investigational Respiratory Syncytial Virus (RSV) Preventative Monoclonal Antibody, Significantly Reduced Incidence of RSV Disease and Hospitalization in Healthy Preterm and Full-term InfantsBusiness Wire • 10/17/24
Merck's CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) Demonstrates Positive Immune Responses in Adults with Increased Risk for Pneumococcal DiseaseBusiness Wire • 10/16/24
Exelixis, MRK Collaborate for Combination Studies on HNSCC and RCCZacks Investment Research • 10/15/24
Exelixis and Merck Sign Clinical Development Collaboration to Evaluate Investigational Zanzalintinib in Combination with KEYTRUDA® (pembrolizumab) in Head and Neck Cancer and in Combination with WELIREG® (belzutifan) in Renal Cell CarcinomaBusiness Wire • 10/14/24
New Data to be Presented at IDWeek 2024 Reinforce Merck's Broad and Diverse Vaccines and Infectious Disease Pipeline and PortfolioBusiness Wire • 10/09/24
Activated Polyethylene Glycol Market Report 2024 - Trends, Forecast and Competitive Analysis to 2030, with Profiles of Leading Players NOF, JenKem Technology, Laysan Bio, Merck Creative and PEGWorksGlobeNewsWire • 10/08/24
Merck's KEYTRUDA® (pembrolizumab) Met Primary Endpoint of Event-Free Survival (EFS) as Perioperative Treatment Regimen in Patients With Resected, Locally Advanced Head and Neck Squamous Cell CarcinomaBusiness Wire • 10/08/24
Flavonoids Market Report 2024-2032, with Profiles of Key Players Alchem, Bordas, Cayman Chemical, Extrasynthese, Flavon USA, Indena, Inodfine Chemical, Nutralliance, Merck and Quercis PharmaGlobeNewsWire • 10/08/24